LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.
| Revenue (TTM) | $262.43M |
| Gross Profit (TTM) | $188.60M |
| EBITDA | $83.02M |
| Operating Margin | 29.00% |
| Return on Equity | 16.80% |
| Return on Assets | 7.44% |
| Revenue/Share (TTM) | $11.53 |
| Book Value | $18.38 |
| Price-to-Book | 4.38 |
| Price-to-Sales (TTM) | 7.04 |
| EV/Revenue | 6.31 |
| EV/EBITDA | 16.49 |
| Quarterly Earnings Growth (YoY) | 22.60% |
| Quarterly Revenue Growth (YoY) | 9.60% |
| Shares Outstanding | $22.87M |
| Float | $21.30M |
| % Insiders | 6.52% |
| % Institutions | 104.31% |
Volatility is currently expanding
BURLINGTON, Mass., Oct. 12, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that it will release its third quarter 2026 financial results on Wednesday, November 4, 2026, after the market close. The company has scheduled a conference call for 5:00 PM EST the same day to discuss the results, business highlights, and company outlook.
LeMaitre Vascular is rated a "Strong Buy" due to its robust M&A-driven business model, high margins, and recent valuation compression. LMAT's strategic shift to larger, higher-multiple acquisitions has improved its success rate to 80% and driven margin expansion, with gross margin rising from 65% to 72%. The company's healthy balance sheet, $376M in cash/short-term investments, and experienced management underpin its ability to pursue disciplined, accretive deals.
National class action law firm offers free, confidential case evaluations to LeMaitre Vascular investors, tenants, partners, and others whose personal information may have been exposed in the reported data breach. NEWTOWN, Pa.
BURLINGTON, Mass., Aug. 27, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will participate in three upcoming investor conferences.
Investors interested in Medical - Products stocks are likely familiar with GE HealthCare Technologies (GEHC) and LeMaitre Vascular (LMAT). But which of these two stocks presents investors with the better value opportunity right now?
LeMaitre Vascular remains a Buy after a 31% pullback, though I have trimmed my price target to $95-$100 for year-end 2027. The Q2 2026 miss was tied to currency, export blockages, and tissue shortages. Not underlying demand. Organic sales grew 10%, and margins hit record highs. Artegraft, now 21% of sales, is LMAT's largest and fastest-growing product. It is the main factor behind margin expansion and international growth prospects.
BURLINGTON, Mass., Aug. 06, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq:LMAT) announced today that management will hold investor meetings at the 11th Annual Needham Virtual MedTech & Diagnostics 1x1 Conference on Tuesday, August 11, 2026.
LeMaitre Vascular, Inc. (LMAT) Q2 2026 Earnings Call Transcript
BURLINGTON, Mass., Aug. 04, 2026 (GLOBE NEWSWIRE) -- LeMaitre Vascular, Inc. (Nasdaq: LMAT), a provider of vascular devices, implants, and services, today reported Q2 2026 results, announced a quarterly dividend of $0.25/share, and provided guidance.
CASY, CLS, PNTG and LMAT stand out for strong interest coverage as borrowing costs rise, with solid sales/EPS growth estimates and big one-year gains.
Tiblio connects your broker and runs your put-and-call-writing strategy for you — on LMAT and any ticker you trade — then tracks every position and per-strategy win rate.
